Guanze Medical Information Industry (Holding) Co., Ltd. (“Guanze Medical”) and FUNDE (Hong Kong) Investment Holdings Co., Limited (“Funde HK”) announced that Funde HK’s mandatory unconditional cash offer closed at 4:00 p.m. on 8 May 2026 without revision or extension.

The offer elicited two valid acceptances, covering 10,000 shares—approximately 0.001 % of Guanze Medical’s 950.00 million issued shares. At the offer price of HK$0.25 per share, total consideration amounted to HK$2,500. Settlement remittances are scheduled to be dispatched within seven business days of each valid acceptance and no later than 19 May 2026.

Following registration of the accepted shares, Funde HK, its ultimate beneficial owners and concert parties will hold 699.17 million shares, maintaining a 73.6 % stake in Guanze Medical. Public shareholders will own 250.83 million shares, or 26.4 % of the total, thereby continuing to satisfy Hong Kong Stock Exchange’s minimum 25 % public-float requirement.

Prior to the offer period, Funde HK acquired 699.16 million shares (73.6 %) from Meng A Capital Limited; no additional on- or off-market purchases occurred during the offer period beyond the aforementioned 10,000 shares.

The shareholding structure at close is as follows: • Funde HK and concert parties: 73.6 % (699.17 million shares) • Public shareholders: 26.4 % (250.83 million shares)

Directors of both entities accept full responsibility for the accuracy of the disclosed information.